@article{bruun_intussusception_2019,
	title = {Intussusception among {Norwegian} children: {What} to expect after introduction of rotavirus vaccination?},
	issn = {1873-2518},
	shorttitle = {Intussusception among {Norwegian} children},
	doi = {10.1016/j.vaccine.2019.06.058},
	abstract = {BACKGROUND: To reduce the risk of vaccine-associated intussusception, rotavirus vaccination in Norway was implemented under strict age limits (the first dose given by 12 weeks of age and the second dose by 16 weeks of age) in 2014. We estimated the incidence of intussusception in children {\textless}2 years old before vaccine introduction and the number of vaccine-associated cases under current and extended age limits for vaccine administration in Norway.
METHODS: To estimate the baseline incidence, we validated all diagnoses in children {\textless}2 years old registered in the national hospital registry during the pre-vaccine period of 2008-2013. Using national vaccine coverage data and international estimates of intussusception risk after rotavirus vaccination, we calculated the numbers of expected vaccine-associated intussusception cases to compare with the estimated numbers of averted rotavirus cases. Uncertainty was accounted for by several scenario analyses using current and extended age limits for vaccine administration.
RESULTS: The pre-vaccine incidence of intussusception was 26.7 (95\% CI 23.1-30.6) cases/year per 100,000 children {\textless}2 years old and 37.1 (95\% CI 31.2-43.8) cases/year per 100,000 children {\textless}1 year old. In the 2016 birth cohort (= approx. 60,000) vaccinated under the current age limits, 1.3 (95\% CI 0.7-2.0) vaccine-associated intussusception cases were expected to occur. If age limits were extended to 16 weeks for the first vaccine dose and 24 weeks for the second dose, leading to more children vaccinated at an older age, 2.2 (95\% CI 1.2-3.5) excess cases would be expected in the same cohort. Simultaneously, an estimated 1768 rotavirus hospitalizations/year in children {\textless}5 years old would be averted under current age limits, with 98 additional rotavirus hospitalizations averted under extended age limits.
CONCLUSIONS: Administering rotavirus vaccines beyond current age limits in Norway would lead to a marginal increase in the number of intussusception cases, which would be offset by the benefits of vaccination.},
	language = {eng},
	journal = {Vaccine},
	author = {Bruun, Tone and Watle, Sara Sofie Viksmoen and Tveteraas, Ingun Heiene and Flem, Elmira},
	month = jun,
	year = {2019},
	pmid = {31255303},
}

{"_id":"jSHaXZv65PAH2dMQG","bibbaseid":"bruun-watle-tveteraas-flem-intussusceptionamongnorwegianchildrenwhattoexpectafterintroductionofrotavirusvaccination-2019","author_short":["Bruun, T.","Watle, S. S. V.","Tveteraas, I. H.","Flem, E."],"bibdata":{"bibtype":"article","type":"article","title":"Intussusception among Norwegian children: What to expect after introduction of rotavirus vaccination?","issn":"1873-2518","shorttitle":"Intussusception among Norwegian children","doi":"10.1016/j.vaccine.2019.06.058","abstract":"BACKGROUND: To reduce the risk of vaccine-associated intussusception, rotavirus vaccination in Norway was implemented under strict age limits (the first dose given by 12 weeks of age and the second dose by 16 weeks of age) in 2014. We estimated the incidence of intussusception in children \\textless2 years old before vaccine introduction and the number of vaccine-associated cases under current and extended age limits for vaccine administration in Norway. METHODS: To estimate the baseline incidence, we validated all diagnoses in children \\textless2 years old registered in the national hospital registry during the pre-vaccine period of 2008-2013. Using national vaccine coverage data and international estimates of intussusception risk after rotavirus vaccination, we calculated the numbers of expected vaccine-associated intussusception cases to compare with the estimated numbers of averted rotavirus cases. Uncertainty was accounted for by several scenario analyses using current and extended age limits for vaccine administration. RESULTS: The pre-vaccine incidence of intussusception was 26.7 (95% CI 23.1-30.6) cases/year per 100,000 children \\textless2 years old and 37.1 (95% CI 31.2-43.8) cases/year per 100,000 children \\textless1 year old. In the 2016 birth cohort (= approx. 60,000) vaccinated under the current age limits, 1.3 (95% CI 0.7-2.0) vaccine-associated intussusception cases were expected to occur. If age limits were extended to 16 weeks for the first vaccine dose and 24 weeks for the second dose, leading to more children vaccinated at an older age, 2.2 (95% CI 1.2-3.5) excess cases would be expected in the same cohort. Simultaneously, an estimated 1768 rotavirus hospitalizations/year in children \\textless5 years old would be averted under current age limits, with 98 additional rotavirus hospitalizations averted under extended age limits. CONCLUSIONS: Administering rotavirus vaccines beyond current age limits in Norway would lead to a marginal increase in the number of intussusception cases, which would be offset by the benefits of vaccination.","language":"eng","journal":"Vaccine","author":[{"propositions":[],"lastnames":["Bruun"],"firstnames":["Tone"],"suffixes":[]},{"propositions":[],"lastnames":["Watle"],"firstnames":["Sara","Sofie","Viksmoen"],"suffixes":[]},{"propositions":[],"lastnames":["Tveteraas"],"firstnames":["Ingun","Heiene"],"suffixes":[]},{"propositions":[],"lastnames":["Flem"],"firstnames":["Elmira"],"suffixes":[]}],"month":"June","year":"2019","pmid":"31255303","bibtex":"@article{bruun_intussusception_2019,\n\ttitle = {Intussusception among {Norwegian} children: {What} to expect after introduction of rotavirus vaccination?},\n\tissn = {1873-2518},\n\tshorttitle = {Intussusception among {Norwegian} children},\n\tdoi = {10.1016/j.vaccine.2019.06.058},\n\tabstract = {BACKGROUND: To reduce the risk of vaccine-associated intussusception, rotavirus vaccination in Norway was implemented under strict age limits (the first dose given by 12 weeks of age and the second dose by 16 weeks of age) in 2014. We estimated the incidence of intussusception in children {\\textless}2 years old before vaccine introduction and the number of vaccine-associated cases under current and extended age limits for vaccine administration in Norway.\nMETHODS: To estimate the baseline incidence, we validated all diagnoses in children {\\textless}2 years old registered in the national hospital registry during the pre-vaccine period of 2008-2013. Using national vaccine coverage data and international estimates of intussusception risk after rotavirus vaccination, we calculated the numbers of expected vaccine-associated intussusception cases to compare with the estimated numbers of averted rotavirus cases. Uncertainty was accounted for by several scenario analyses using current and extended age limits for vaccine administration.\nRESULTS: The pre-vaccine incidence of intussusception was 26.7 (95\\% CI 23.1-30.6) cases/year per 100,000 children {\\textless}2 years old and 37.1 (95\\% CI 31.2-43.8) cases/year per 100,000 children {\\textless}1 year old. In the 2016 birth cohort (= approx. 60,000) vaccinated under the current age limits, 1.3 (95\\% CI 0.7-2.0) vaccine-associated intussusception cases were expected to occur. If age limits were extended to 16 weeks for the first vaccine dose and 24 weeks for the second dose, leading to more children vaccinated at an older age, 2.2 (95\\% CI 1.2-3.5) excess cases would be expected in the same cohort. Simultaneously, an estimated 1768 rotavirus hospitalizations/year in children {\\textless}5 years old would be averted under current age limits, with 98 additional rotavirus hospitalizations averted under extended age limits.\nCONCLUSIONS: Administering rotavirus vaccines beyond current age limits in Norway would lead to a marginal increase in the number of intussusception cases, which would be offset by the benefits of vaccination.},\n\tlanguage = {eng},\n\tjournal = {Vaccine},\n\tauthor = {Bruun, Tone and Watle, Sara Sofie Viksmoen and Tveteraas, Ingun Heiene and Flem, Elmira},\n\tmonth = jun,\n\tyear = {2019},\n\tpmid = {31255303},\n}\n\n","author_short":["Bruun, T.","Watle, S. S. V.","Tveteraas, I. H.","Flem, E."],"key":"bruun_intussusception_2019","id":"bruun_intussusception_2019","bibbaseid":"bruun-watle-tveteraas-flem-intussusceptionamongnorwegianchildrenwhattoexpectafterintroductionofrotavirusvaccination-2019","role":"author","urls":{},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/robin.marlow","dataSources":["ix72eqAAMGCuupBaz"],"keywords":[],"search_terms":["intussusception","norwegian","children","expect","introduction","rotavirus","vaccination","bruun","watle","tveteraas","flem"],"title":"Intussusception among Norwegian children: What to expect after introduction of rotavirus vaccination?","year":2019}